Novel cardiac biomarkers (Serum S100A12 (Calgranulin C), FSTL1 (Follistatin-like 1), and Osteocalcin) in patients with Acute Chest Pain

Novel cardiac biomarkers in patients with Acute Chest Pain

  • Wenjing Xie Department of Emergency, The Affiliated Suzhou Hospital of Nanjing University Medical School, Suzhou, Jiangsu 215000, China
  • Wei Zhao Department of Nursing, The Affiliated Suzhou Hospital of Nanjing University Medical School, Suzhou, Jiangsu 215000, China
  • Hongtao Wang Department of Emergency, The Affiliated Suzhou Hospital of Nanjing University Medical School, Suzhou, Jiangsu 215000, China
  • Yuanguang Xie Department of Emergency, The Affiliated Suzhou Hospital of Nanjing University Medical School, Suzhou, Jiangsu 215000, China
  • Luyan Gu Department of Emergency, The Affiliated Suzhou Hospital of Nanjing University Medical School, Suzhou, Jiangsu 215000, China
DOI: https://doi.org/10.5937/jomb0-58940
Keywords: S100A12 (Calgranulin C), FSTL1 (Follistatin-like 1), Osteocalcin, acute chest pain, optimized emergency nursing, cardiac biomarkers, inflammatory markers, biomarkers, rescue, adverse events, pain

Abstract


Objective: To evaluate the impact of an optimized emergency care process on clinical outcomes and potential biochemical markers associated with acute chest pain (ACP). This study investigates whether improved emergency protocols can influence the release of key cardiac biomarkers and inflammatory mediators in ACP patients.

Methods: A total of 116 ACP patients admitted to the emergency department were divided into a research group (RG) receiving optimized emergency nursing procedures and a control group (CG) receiving routine nursing procedures. Clinical parameters, including triage assessment time, emergency time, hospital stay, success rate of rescue, mortality rate, and incidence of adverse events, were compared. Additionally, serum levels of cardiac biomarkers (e.g., troponin I, creatine kinase-MB) and inflammatory markers (e.g., C-reactive protein, interleukin-6) were measured at baseline and at specified time points post-intervention to assess the biochemical impact of the emergency care intervention. Biomarkers such as S100A12 (Calgranulin C), FSTL1 (Follistatin-like 1), and Osteocalcin (hormonal biomarker)were also included to explore additional biochemical pathways relevant to cardiac stress, inflammation, and vascular function. Patient satisfaction was evaluated.

Results: The RG showed significantly shorter triage assessment time, emergency time, and hospital stay compared to the CG (P<0.05). The success rate of rescue was higher, and the mortality rate was lower in the RG (P<0.05). VAS scores for pain were also significantly lower in the RG at 0.5 h, 1.0 h, 2.0 h, and 4.0 h after rescue (P<0.05). Furthermore, the incidence of adverse reactions was lower, and nursing satisfaction was higher in the RG (P<0.05). Biochemically, serum levels of troponin I, CK-MB, CRP, and IL-6 were reduced post-intervention in the RG, suggesting a lower degree of myocardial injury and systemic inflammation. Additionally S100A12 and FSTL1 were significantly lower in the RG, indicating reduced inflammatory and myocardial stress responses. Osteocalcin levels demonstrated a correlation with improved metabolic and vascular function in ACP patients.

Conclusion: An optimized emergency care process in ACP patients improves clinical outcomes, potentially by influencing the downstream release or modulation of biochemical markers associated with cardiac stress and inflammation. The observed reductions in S100A12, FSTL1, and modulation of osteocalcin, alongside decreased troponin I, CK-MB, CRP, and IL-6, suggest that emergency care protocols may have a direct biochemical impact on cardiac and inflammatory pathways. Further studies are warranted to explore the direct biochemical impact of optimized care interventions on cardiac biomarker profiles and inflammatory responses in ACP patients.

Published
2025/10/29
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 Wenjing Xie, Wei Zhao, Hongtao Wang, Yuanguang Xie, Luyan Gu

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.